Vaxcyte Inc (NASDAQ:PCVX) — Market Cap & Net Worth
Market Cap & Net Worth: Vaxcyte Inc (PCVX)
Vaxcyte Inc (NASDAQ:PCVX) has a market capitalization of $8.81 Billion ($8.81 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2460 globally and #904 in its home market, demonstrating a -3.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vaxcyte Inc's stock price $59.21 by its total outstanding shares 148805278 (148.81 Million). Also see balance sheet size of Vaxcyte Inc for a full breakdown of the balance sheet.
Vaxcyte Inc Market Cap History: 2020 to 2026
Vaxcyte Inc's market capitalization history from 2020 to 2026. Data shows growth from $3.95 Billion to $8.81 Billion (13.94% CAGR). Also see PCVX cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Vaxcyte Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.33% | #55 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.02% | #283 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.47% | #37 of 263 |
Weight: Vaxcyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vaxcyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vaxcyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Vaxcyte Inc (PCVX) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PCVX by Market Capitalization
Companies near Vaxcyte Inc in the global market cap rankings as of September 16, 2026. Review PCVX goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Vaxcyte Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Vaxcyte Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Vaxcyte Inc's market cap moved from $3.95 Billion to $ 8.81 Billion, with a yearly change of 13.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.81 Billion | +28.33% |
| 2025 | $6.87 Billion | -43.64% |
| 2024 | $12.18 Billion | +30.35% |
| 2023 | $9.34 Billion | +30.97% |
| 2022 | $7.14 Billion | +101.56% |
| 2021 | $3.54 Billion | -10.46% |
| 2020 | $3.95 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Vaxcyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.81 Billion USD |
| MoneyControl | $8.81 Billion USD |
| MarketWatch | $8.81 Billion USD |
| marketcap.company | $8.81 Billion USD |
| Reuters | $8.81 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more